Last reviewed · How we verify
UFT (uracil, tegafur)
UFT is a combination of uracil and tegafur that inhibits thymidylate synthase to block DNA synthesis and induce cancer cell death.
UFT is a combination of uracil and tegafur that inhibits thymidylate synthase to block DNA synthesis and induce cancer cell death. Used for Colorectal cancer, Gastric cancer, Breast cancer.
At a glance
| Generic name | UFT (uracil, tegafur) |
|---|---|
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Drug class | Fluoropyrimidine antimetabolite |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tegafur is a prodrug of 5-fluorouracil (5-FU) that is converted in the body to the active form. Uracil is included to inhibit dihydropyrimidine dehydrogenase, the enzyme responsible for 5-FU catabolism, thereby increasing and prolonging 5-FU exposure. Together, they act as a fluoropyrimidine antimetabolite that disrupts nucleotide synthesis and DNA replication in rapidly dividing cancer cells.
Approved indications
- Colorectal cancer
- Gastric cancer
- Breast cancer
Common side effects
- Bone marrow suppression (leukopenia, thrombocytopenia)
- Gastrointestinal toxicity (nausea, diarrhea, stomatitis)
- Hand-foot syndrome
- Fatigue
- Anemia
Key clinical trials
- Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer (PHASE3)
- Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer (PHASE3)
- A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA (PHASE3)
- A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy (PHASE2)
- Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer (PHASE2)
- Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma (PHASE3)
- A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors (PHASE1)
- Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+ (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UFT (uracil, tegafur) CI brief — competitive landscape report
- UFT (uracil, tegafur) updates RSS · CI watch RSS
- Taiho Pharmaceutical Co., Ltd. portfolio CI